Boston Biomedical (United States)

Recent papers from Boston Biomedical (United States)

1. A synthetic NKG2A engager enables long-term persistence of HLA-deficient allogeneic engineered TregsEMBO Molecular Medicine · 2026
2. 2386-P: Autoantibody-Negative Insulin-Deficient Individuals in the Rare and Atypical Diabetes Network (RADIANT)Diabetes · 2026
3. 2962-LB: CGM Metrics and Cardiovascular and Mortality Outcomes in Type 2 Diabetes: Data from the GRADE-CGM SubstudyDiabetes · 2026
4. Mechanistic insights into lenacapavir-induced off-pathway HIV-1 capsid assembly2026
5. Leveraging simulation to provide a practical framework for estimating the novel scope of risk of large language models in healthcareBMJ Mental Health · 2026
6. Development and external validation of a computational approach for accelerated read out of randomized clinical trials in metastatic prostate cancer.Journal of Clinical Oncology · 2026
7. Mapping the avoid-ome: a systematic open-science approach to predictive ADMETNature Communications · 2026
8. TCT-425 Innervation Patterns in the Renal Artery Ostium May Limit the Efficacy of Endovascular Radiofrequency AblationJournal of the American College of Cardiology · 2014
9. Circularly Polarized Metamaterial Cage for Homogeneous Signal‐to‐Noise Ratio Enhancement in Magnetic Resonance ImagingAdvanced Materials · 2026
10. Abstract LB070: Discovery of Helicon peptides that selectively degrade the agonist-bound androgen receptor (ARON) in prostate cancerCancer Research · 2026
11. Abstract 3972: Comprehensive immune landscape analysis of solid tumors using a 17-Plex immunofluorescence assay in clinical trialsCancer Research · 2026
12. Abstract 3099: Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysisCancer Research · 2026
13. Abstract 5173: Identification of a small molecule degrader targeting SALL4 oncogeneCancer Research · 2026
14. Abstract PR010: ERK hyperactivation-induced lethality as a therapeutic strategy in RAS-driven tumorsCancer Research · 2026
15. Phase 1 dose escalation and expansion of AB001 in patients with metastatic castration resistant prostate cancer (mCRPC): The ARTISAN trial.Journal of Clinical Oncology · 2026
16. Developing Medical Cannabis CompetenciesJAMA Network Open · 2025
17. Acetazolamide Plus Atomoxetine for Obesity Hypoventilation Syndrome TreatmentCHEST Journal · 2025
18. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening - The VICTORION-PLAQUE primary prevention trialAmerican Heart Journal · 2025
19. Decoding BCL6 Inhibitors: Computational Insights into the Impact of Water Networks on PotencyJournal of Chemical Information and Modeling · 2025
20. Implementation of Systems to Support Status-Neutral HIV Care in the Emergency DepartmentSexually Transmitted Diseases · 2025